Funding new treatments for low grade serous ovarian cancer
Target Ovarian Cancer is announcing a brand new award for research into a less common type of this disease.
Target Ovarian Cancer is announcing a brand new award for research into a less common type of this disease.
Gamechanging drug olaparib is now available from beginning of treatment across the UK.
Today we've released new research on how much women know about breast cancer and ovarian cancer symptoms.
News from the European Society of Medical Oncology (ESMO) conference means more women could be able to access innovative treatments earlier.
Transformational funding from the Peter Sowerby Foundation will help us tackle the problem in a radically new way.
Zahra shares the motivation for her research in our TAKE OVAR campaign.
Sign up to receive emails and keep up to date on all things Target Ovarian Cancer
Sign up